$tr2['classname']

肺癌

$tr2['classname']

乳腺癌

$tr2['classname']

结直肠癌

$tr2['classname']

前列腺癌

$tr2['classname']

甲状腺癌

$tr2['classname']

宫颈癌

$tr2['classname']

胃癌

$tr2['classname']

肝癌

$tr2['classname']

胆囊癌

$tr2['classname']

卵巢癌

$tr2['classname']

食管癌

$tr2['classname']

胰腺癌

$tr2['classname']

膀胱癌

$tr2['classname']

淋巴瘤

$tr2['classname']

子宫内膜癌

$tr2['classname']

肾癌

$tr2['classname']

罕见肿瘤

首页 > TAG信息列表 > CheckMate-9DW2

纳武利尤单抗|最新研究

肝癌一线双免疫疗法获批:中位生存期23.7个月
  • 肝癌一线双免疫疗法获批:中位生存期23.7个月
  • 百时美施贵宝的Opdivo(纳武利尤单抗)与Yervoy(伊匹木单抗)双免疫组合疗法获NMPA与FDA批准用于不可切除肝细胞癌一线治疗。CheckMate-9DW2研究显示,该组合中位总生存期达23.7个月,客观缓解率36%,中位缓解持续时间30.4个月。...|阅读全文
  • 发布日期 2026-09-18 09:44:41